Targeting Psychosis in Alzheimer’s Disease
About this episode
The episode discusses the under-recognized issue of psychosis in Alzheimer's disease and features an interview with Elizabeth Thompson about potential therapies.
Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care impossible is not cognition—it is psychosis. Hallucinations and delusions in Alzheimer’s are a distinct, prevalent, and under-recognized target for therapy. We spoke to Elizabeth Thompson, executive vice president and head of R&D at Acadia Pharmaceuticals, about the biology behind psychosis in dementia, the company’s experimental therapy to treat the condition in people with Alzheimer’s disease, and the forces reshaping the drug development landscape to enable the development of such treatments.
People in this episode
Guest: Elizabeth Thompson
Mentioned in this episode
Organizations: Acadia Pharmaceuticals
Books & works: Alzheimer’s disease
More episodes of The Bio Report
- Slowing Disability in MS
- Tuning, Rather than Blocking, Immunity in IBD
- Intercepting Cancer When DNA Surveillance Fails
- A Class Action Suits Moves RICO from Mobsters to Medicine
- Outsmarting Resistance with Rhythm
- Editing Away Autoimmunity at the HLA Source
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.